Drugs / SGB-3908
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06501586 | Jul 2024 → Apr 2025 | essential hypertension | Suzhou Sanegene Bio Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-11-10 | Innovent Biologics (Suzhou) Co. Ltd. | Results Innovent and SanegeneBio Announce Phase 1 Clinical Data for IBI3016 Presented at American Heart Association (AHA) 2025 Annual Meeting innoventbio.com ↗
IBI3016 demonstrates sustained and potent AGT mRNA suppression with preliminary evidence of antihypertensive efficacy after single-dose subcutaneous administration. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-11-10 | Innovent Biologics (Suzhou) Co. Ltd. | Innovent and SanegeneBio Announce Phase 1 Clinical Data for IBI3016 Presented at American Heart Association (AHA) 2025 Annual Meeting innoventbio.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SGB-3908 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06501586 ↗ |
| Route | Subcutaneous | “SGB-3908 for sc injection” NCT06501586 ↗ |